SIGA

SIGA Technologies, Inc. - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the sale of its lead product, TPOXX® (tecovirimat), an antiviral for smallpox treatment. The company primarily serves the U.S. Government (via the Strategic National Stockpile) and international governments. As of July 24, 2026, the company had 71,849,716 shares of common stock outstanding.

Key Financial Metrics

Margins: Gross margin for the six months ended June 30, 2026, was approximately 56.4% ($26.7 million gross profit / $47.2 million revenue). The effective tax rate for the six-month period was 16.6%.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for the six months ended June 30, 2026, decreased by approximately 46% compared to the same period in 2025 ($47.2 million vs. $88.2 million). This was driven primarily by a significant reduction in oral TPOXX® sales to the U.S. Government, which were $53.3 million in the prior year period but absent in the current period's product sales breakdown.
• Product Mix Shift: Current period product sales were dominated by IV TPOXX® deliveries to the U.S. Government ($25.6 million) and international sales ($13.0 million), whereas the prior period included substantial oral TPOXX® deliveries.
• Profitability: Net income decreased significantly year-over-year ($9.0 million vs. $35.1 million) due to lower revenue volumes, despite operating expenses remaining relatively controlled.
• Liquidity: Cash and cash equivalents decreased by $37.4 million during the six-month period, primarily due to a special cash dividend payment of $43.3 million.

Guidance, Outlook, and Risks

• Regulatory Developments (Mpox): The European Medicines Agency (EMA) and UK MHRA have removed the mpox indication from the Tecovirimat-SIGA label following clinical trial results (PALM 007, STOMP, UNITY) that did not meet primary endpoints for mpox treatment. The product retains approval for smallpox, cowpox, and vaccinia complications.
• Contract Status: The 19C BARDA contract remains the primary revenue driver, with approximately $630 million in total potential payments. As of June 30, 2026, $545.2 million in options have been exercised. The company expects to submit a Supplemental NDA for a smallpox post-exposure prophylaxis (PEP) indication in the first half of 2027.
• International Expansion: In March 2026, SIGA entered an exclusive license agreement with Hikma MENA FZE for the Middle East and North Africa region. The International Promotion Agreement with Meridian expired on May 31, 2026.
• Risks: Key risks include the failure to secure new U.S. Government contracts to maintain stockpile levels, supply chain disruptions, and the impact of tariffs on IV TPOXX® manufacturing costs. Management forecasts potential losses for the full year based on current orders, impacting the effective tax rate.

Investor Verification Checklist

• Contract Renewals: Verify the status of new procurement orders from the U.S. Government to replace the oral TPOXX® volumes delivered in 2025.
• International Sales Sustainability: Assess the durability of the $13.0 million in international sales recognized in the first half of 2026 and the impact of the new Hikma MENA agreement.
• Regulatory Impact: Monitor the impact of the EMA/MHRA label change regarding mpox on future international demand and pricing.
• Cash Burn vs. Dividends: Evaluate the sustainability of the $0.60 per share special dividend policy given the reduced revenue environment and the company's cash balance of $117.6 million.
• IV TPOXX Margins: Confirm the gross margin profile for IV TPOXX® (estimated <40% by management) as it becomes a larger portion of the revenue mix.